Keratinocyte

Bestqool Launches Innovative Red Light Therapy Devices for Eczema Relief

Retrieved on: 
Friday, April 5, 2024
Skin care, Fibroblast, Health, Certification, RLT, Psoriasis, Adenosine triphosphate, Cell, Serotonin, Patient, Photobiology, Tissue, Rosacea, Mitochondrion, Mental health, History, Red, Quality of life, Dermatitis, Itch, Keratinocyte, Acne, Skin, Pollution, Erythema, Cytokine, Irritation, ATP, Immune system, Recurrence, Fatigue, Swelling, FDA, Waste, Medical device

Bestqool's advanced red light therapy offers a non-invasive, natural solution for managing this pervasive skin issue.

Key Points: 
  • Bestqool's advanced red light therapy offers a non-invasive, natural solution for managing this pervasive skin issue.
  • Combining red light therapy with topical ointments can be a complementary approach for effective eczema treatment.
  • Bestqool's latest range of portable red light therapy devices are designed to be both convenient and effective for home use.
  • Adding red light therapy to daily care and prevention can repair both inside and outside by lowering eczema recurrence and improving the quality of life.

Rejuvenate Bio Announces Gene Therapy-Mediated Partial Reprogramming Extends Lifespan and Reverses Age-Related Changes in the Journal Cellular Reprogramming

Retrieved on: 
Thursday, February 22, 2024
Research, Genetics, Cardiology, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Ageing, Mouse, KLF4, Notifiable disease, Vivisection, Stem cell, Scalp, Biomarker, OSK, Keratinocyte, Heart, Male, Yamanaka, AAV, DNA methylation, DNA, Vaccine

The study, titled " Gene Therapy-Mediated Partial Reprogramming Extends Lifespan and Reverses Age-Related Changes in Aged Mice ," reveals promising advancements in combating age-related diseases and extending lifespan through cellular rejuvenation.

Key Points: 
  • The study, titled " Gene Therapy-Mediated Partial Reprogramming Extends Lifespan and Reverses Age-Related Changes in Aged Mice ," reveals promising advancements in combating age-related diseases and extending lifespan through cellular rejuvenation.
  • While aging cannot be prevented, interventions targeting cellular processes offer potential for mitigating its impact on health and lifespan in the elderly.
  • Rejuvenate Bio's research focuses on partial reprogramming using the Yamanaka factors, specifically OCT4, SOX2, and KLF4 (OSK), to reverse age-related changes.
  • These results may have important implications for the development of partial reprogramming interventions to reverse age-associated diseases in the elderly population.”

Collaboration Between CEA and FLASH THERAPEUTICS for the Development of Cutaneous Cell Therapy

Retrieved on: 
Monday, February 5, 2024
Research, Genetics, Biotechnology, Other Health, Health, General Health, Other Science, Science, Oncology, Partnership, CDMO, KLF4, Flash, CEA, Skin, Therapy, Keratinocyte, Collaboration

Thanks to the quality of Flash Therapeutics' vectors, the LGRK has been sourcing specific products from our company for over 10 years to support its research activities, in particular, to study the intrinsic properties and regenerative capacity of skin stem cells.

Key Points: 
  • Thanks to the quality of Flash Therapeutics' vectors, the LGRK has been sourcing specific products from our company for over 10 years to support its research activities, in particular, to study the intrinsic properties and regenerative capacity of skin stem cells.
  • Flash Therapeutics and the CEA's Institut de biologie François Jacob are currently discussing expanding their partnership, given their complementary nature.
  • Jérôme Bédier, CEO of Flash Therapeutics: "We are delighted to be partnering with the CEA, the leading French and European player in the field of energy and technology.
  • This approach builds on more than 10 years of collaboration and is in line with Flash's key mission: to discover and bring forward innovative technologies for highly effective therapies on a commercial scale ".

Enable Medicine Announces Publication in Science Immunology Showing Spatial Transcriptomics Reveal Distinct Mechanisms of Response to Psoriasis Therapy

Retrieved on: 
Monday, January 29, 2024
Technology, Biotechnology, FDA, Health, Other Health, Pharmaceutical, Artificial Intelligence, Other Science, Research, Software, Genetics, Science, Data Management, Clinical Trials, Entrepreneurship, Patient, UCSF, Drug resistance, Associate, MD, PV, Paper, Cytokine, Drug discovery, Skin, Psoriasis, Disease, Doctor of Philosophy, Inflammation, Keratinocyte, Science Immunology, Pharmaceutical industry

The paper titled: " A single-cell atlas of IL-23 inhibition in cutaneous psoriasis distinguishes clinical response ," details crucial insights into the mechanisms underlying treatment response and resistance in psoriasis patients receiving IL-23 blockade.

Key Points: 
  • The paper titled: " A single-cell atlas of IL-23 inhibition in cutaneous psoriasis distinguishes clinical response ," details crucial insights into the mechanisms underlying treatment response and resistance in psoriasis patients receiving IL-23 blockade.
  • Psoriasis vulgaris and other chronic inflammatory diseases improve markedly with therapeutic blockade of IL-23 signaling, but the genetic mechanisms underlying clinical responses remain poorly understood.
  • Using single cell transcriptomics, researchers profiled immune cells isolated from lesional psoriatic skin before and during IL-23 blockade.
  • “This study offers unprecedented insights into the molecular mechanisms underlying treatment response and resistance in psoriasis.

Turn Biotechnologies' Expanded eTurna™ Delivery Platform Designed to Solve Delivery and Targeting Issues that Challenge Industry

Retrieved on: 
Wednesday, January 3, 2024
Particle size, Messenger, Fibroblast, PEG, Tissue, Macrophage, Ionization, Keratinocyte, Lipid, Blood, Endothelium, Transfection, Cell, Safety, Medicine, Skin, Vaccine

The proprietary ionizable lipids used in the eTurna™ delivery platform are safer as they are biodegradable, non-toxic and clear the body faster, while providing higher encapsulation capacity and cargo loading.

Key Points: 
  • The proprietary ionizable lipids used in the eTurna™ delivery platform are safer as they are biodegradable, non-toxic and clear the body faster, while providing higher encapsulation capacity and cargo loading.
  • Since the platform can utilize PEG-free stabilizing components, the delivery system minimizes or eliminates immunogenicity associated with PEG lipids currently used in LNPs.
  • "It is designed to enable the delivery of therapies to treat incurable diseases by targeting cells that medicine cannot currently reach.
  • Turn Bio's first drug candidates are focused on treating the skin by targeting specific cells including fibroblasts, endothelial cells and keratinocytes.

Turn Biotechnologies' Expands eTurna™ Delivery Platform to Solve Delivery and Targeting Issues that Challenge Industry

Retrieved on: 
Wednesday, January 3, 2024
Particle size, Messenger, Fibroblast, PEG, Tissue, Macrophage, Ionization, Keratinocyte, Lipid, Blood, Endothelium, Transfection, Cell, Safety, Medicine, Skin, Vaccine

The proprietary ionizable lipids used in the eTurna™ delivery platform are safer as they are biodegradable, non-toxic and clear the body faster, while providing higher encapsulation capacity and cargo loading.

Key Points: 
  • The proprietary ionizable lipids used in the eTurna™ delivery platform are safer as they are biodegradable, non-toxic and clear the body faster, while providing higher encapsulation capacity and cargo loading.
  • Since the platform can utilize PEG-free stabilizing components, the delivery system minimizes or eliminates immunogenicity associated with PEG lipids currently used in LNPs.
  • "It is designed to enable the delivery of therapies to treat incurable diseases by targeting cells that medicine cannot currently reach.
  • Turn Bio's first drug candidates are focused on treating the skin by targeting specific cells including fibroblasts, endothelial cells and keratinocytes.

Derm-Biome Pharmaceuticals Announces Collaboration with Massachusetts General Hospital in Skin Cancer Study

Retrieved on: 
Tuesday, November 28, 2023
Associate, Skin, Death, Apoptosis, Massachusetts General Hospital, Research, Skin cancer, Keratinocyte, University, Toxicity, Cell, University of British Columbia, Harvard Medical School, Pharmaceutical industry

VANCOUVER, British Columbia, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals Inc, a Vancouver based biopharmaceutical company with a focus on skin disease, is excited to announce that it is collaborating with Dr. Anna Mandinova from the Department of Dermatology at Massachusetts General Hospital in a skin cancer study.

Key Points: 
  • VANCOUVER, British Columbia, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals Inc, a Vancouver based biopharmaceutical company with a focus on skin disease, is excited to announce that it is collaborating with Dr. Anna Mandinova from the Department of Dermatology at Massachusetts General Hospital in a skin cancer study.
  • Derm-Biome has developed a second-generation topical treatment for precancerous skin conditions (such as actinic keratosis) and non-melanoma skin cancers that is highly selective for cancer cells while being well-tolerated by normal skin.
  • Soaring skin cancer rates are reaching all-time highs in many parts of the world, and there are now more global deaths from non-melanoma skin cancers than melanoma itself.
  • Dr. Anna Mandinova, Associate Professor, Harvard Medical School, and Associate Director of the Massachusetts General Hospital Cutaneous Biology Research Center says: “My lab previously treated primary patient-derived squamous cell carcinoma cells and normal keratinocytes with a Derm-Biome compound.

ROME Therapeutics Presents First Data to Validate LINE-1 RT as a Novel Target in Autoimmune Diseases and the Therapeutic Potential of its First-in-Class LINE-1 RT Inhibitors

Retrieved on: 
Thursday, November 16, 2023
Health, Biotechnology, DNA, Therapy, Pathology, University, Cytoplasm, Keratinocyte, Patient, UV, Autoantibody, American College of Rheumatology, Autoimmune disease, Heart, Kidney, American College, SLE, DSM-IV codes, Drug discovery, RT, RNA, AGS, Skin, ACR, Quality of life, Lupus, Poster, Biology, Inflammation, Pharmaceutical industry, Vaccine, Rheumatology

Data also demonstrated the therapeutic potential of the company’s first-in-class LINE-1 RT inhibitors to stop disease-driving inflammation.

Key Points: 
  • Data also demonstrated the therapeutic potential of the company’s first-in-class LINE-1 RT inhibitors to stop disease-driving inflammation.
  • Additionally, the poster highlighted the first preclinical data demonstrating the therapeutic potential of ROME’s first-in-class inhibitors of LINE-1 RT.
  • These data are the first to validate LINE-1 RT as a novel target for potential therapeutic intervention across a wide range of autoimmune diseases,” said Rosana Kapeller, M.D., Ph.D., President, CEO and Co-founder of ROME.
  • “We’re also pleased to share the first in vivo and in vitro data validating the therapeutic effect of our first-in-class LINE-1 RT inhibitors in the autoimmune disease setting.

NUS scientists develop innovative magnetic gel that heals diabetic wounds three times faster

Retrieved on: 
Thursday, October 19, 2023
Wuhan University of Technology, FDA, Engineering, NUS, Connective tissue, Yale-NUS College, Burns, Patent, Hydrogel, Keratinocyte, Orthopedic surgery, National University of Singapore, Agency, Sun, Diabetes, Infection, Nanyang Technological University, Wallace H. Coulter Department of Biomedical Engineering, Sengkang General Hospital, Cell, Fibroblast, Multimedia, Collagen, Quality of life, Tissue, Regeneration, Advanced Materials, Recurrence, Walking, National university, Agency for Science, Technology and Research, Blood, Overalls, Ulcer, Wound healing, Amputation, Patient, Biomedicine, Communication, Consultant, Biomedical engineering, Medical imaging, Electric motor, Nursing, Pharmaceutical industry, Dentistry, Research, Science

SINGAPORE, Oct. 19, 2023 /PRNewswire/ -- Diabetic patients, whose natural wound-healing capabilities are compromised, often develop chronic wounds that are slow to heal. Such non-healing wounds could cause serious infections resulting in painful outcomes such as limb amputation. To address this global healthcare challenge, a team of researchers from the National University of Singapore (NUS) engineered an innovative magnetic wound-healing gel that promises to accelerate the healing of diabetic wounds, reduce the rates of recurrence, and in turn, lower the incidents of limb amputations.

Key Points: 
  • Lab tests showed the treatment coupled with magnetic stimulation healed diabetic wounds about three times faster than current conventional approaches.
  • Furthermore, while the research has focussed on healing diabetic foot ulcers, the technology has potential for treating a wide range of complex wounds such as burns.
  • Chronic diabetic wounds such as foot ulcers (one of the most common and hardest to treat wounds) have therefore become a major global healthcare challenge.
  • While the magnetic wound-healing gel has shown great promise in improving diabetic wound healing, it could also revolutionise the treatment of other complex wound types.

Serucell selected as a partner for the Rolls-Royce Enthusiast Club "Strive for Perfection" publication and showcase

Retrieved on: 
Tuesday, September 26, 2023
Elasticity, RREC, Keratinocyte, Rolls-Royce, International Club Crosby, CCT, Medicine, Research, Cell, Fibroblast, Science, Regeneration, Beauty, Serum, Grosvenor House, Rolls-Royce Motor Cars, House, St James's, Skin, Carbon fibers, Pharmaceutical industry, Cosmetics

HUNTINGTON, W.Va., Sept. 26, 2023 /PRNewswire-PRWeb/ -- The founders of Serucell are proud to announce the brand's inclusion in this year's Strive for Perfection: Celebrating 20 years of Goodwood – an official publication for the International Club for Rolls-Royce and Bentley Enthusiasts. This prestigious car club with a lasting heritage is set to launch the new 400-page hardback, remarkably illustrated coffee-table book at Grosvenor House hotel in central London on Friday, October 6, 2023.

Key Points: 
  • Serucell, a small West Virginia science-based luxury skincare company founded by doctors that use bio-cellular research to create proprietary and patented beauty products, has been selected as a partner for the Rolls-Royce Enthusiast Club "Strive for Perfection" publication and showcase.
  • Resonating with the theme of sustainable luxury, Serucell will enable guests at the reception to indulge in the first and only dual-cell skincare technology skincare products.
  • Serucell is a science-based luxury skincare company founded by doctors that use bio-cellular research to create proprietary products that feature KFS® Cellular Protein Complex.
  • Serucell' s multi-patented dual cell technology harnesses the power of keratinocytes and fibroblasts, two essential contributors to maintaining healthy skin.